rifamycin-sv has been researched along with Pain* in 3 studies
1 trial(s) available for rifamycin-sv and Pain
Article | Year |
---|---|
Multiple intra-articular treatment of rheumatoid arthritis: a randomized prospective study comparing rifamycin SV with pefloxacin.
In a randomized, prospective study the efficacy and tolerability of extensive multiple intra-articular administrations of two antibiotics, rifamycin SV and pefloxacin, were evaluated in 40 patients with classical or definite rheumatoid arthritis. Total weekly doses of 525 mg rifamycin or 560 mg pefloxacin were given for 10 weeks, and 12 months after treatment all clinical indices, erythrocyte sedimentation rate and C-reactive protein improved significantly in the rifamycin group. Some of the treatment indices (morning stiffness, severity of pain by visual analogue scale, grip strength and Ritchie's index) were already improved when the treatment ended, whereas others (erythrocyte sedimentation rate, C-reactive protein, number of painful and swollen joints) improved progressively during the follow-up. In the pefloxacin treatment group all indices except C-reactive protein and severity of pain determined using a visual analogue scale were significantly improved 12 months after treatment. Comparison of the two treatments showed a significant difference in erythrocyte sedimentation rate (P less than 0.047), Ritchie's index (P less than 0.036) and C-reactive protein (P less than 0.028) in favour of rifamycin. Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Humans; Injections, Intra-Articular; Middle Aged; Pain; Pefloxacin; Prospective Studies; Rifamycins | 1992 |
2 other study(ies) available for rifamycin-sv and Pain
Article | Year |
---|---|
Clinical improvement in ankylosing spondylitis with rifamycin SV infiltrations of peripheral joints.
In an open study, a new treatment modality was evaluated in 22 patients with active ankylosing spondylitis and compared with oral treatment. Patients were given a 10-week course of rifamycin SV infiltrations to all large peripheral joints, whether or not affected, and were followed for up to 12 months after the end of treatment. Clinical improvements observed at the end of the 10-week treatment cycle persisted for 12 months: morning stiffness (P less than 0.02); subjective pain (P less than 0.0001); Schober's test (P less than 0.006); hand-ground distance (P less than 0.001); erythrocyte sedimentation rate (P less than 0.001); and C-reactive protein (P less than 0.04). The number of painful joints became significantly lower at 6 (P less than 0.01) and 12 months (P less than 0.02) of the follow-up period. Oral administration of rifampin at three times the intra-articular dosage was devoid of any therapeutic activity. It is not known how treatment of peripheral joints influenced the inflammatory process at the level of the axial skeleton. These results must be considered preliminary due to the small number of patients and the short follow-up period, and because it was an open study. Topics: Administration, Oral; Adult; Female; Humans; Inflammation; Injections, Intra-Articular; Male; Pain; Rifampin; Rifamycins; Spondylitis, Ankylosing | 1992 |
[RIFAMYCIN SV IN THE TREATMENT OF SOME POSTOPERATIVE COMPLICATIONS OF ECHINOCOCCAL CYSTS OF LIVER].
Topics: Adolescent; Chloramphenicol; Cysts; Echinococcosis; Echinococcosis, Hepatic; Fever; Jaundice; Liver; Oxytetracycline; Pain; Penicillins; Postoperative Complications; Rifamycins; Sepsis; Streptomycin; Suppuration; Surgical Procedures, Operative | 1964 |